PROCEPT BioRobotics (NASDAQ:PRCT) CEO Larry Wood Purchases 23,900 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) CEO Larry Wood purchased 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $20.41 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. PROCEPT BioRobotics Corporation has a fifty-two week low of $16.67 and a fifty-two week high of $42.71. The firm has a market capitalization of $1.16 billion, a PE ratio of -10.52 and a beta of 0.89. The stock’s 50-day simple moving average is $21.59 and its 200-day simple moving average is $24.75.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same period in the previous year, the business posted ($0.35) EPS. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on PRCT shares. Evercore set a $23.00 target price on PROCEPT BioRobotics in a research report on Wednesday. Truist Financial set a $21.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday. Piper Sandler reduced their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $28.00.

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds have recently added to or reduced their stakes in PRCT. Advisory Services Network LLC grew its position in PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after acquiring an additional 250 shares during the period. Osaic Holdings Inc. increased its holdings in PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after purchasing an additional 337 shares in the last quarter. ProShare Advisors LLC raised its position in PROCEPT BioRobotics by 4.7% in the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock valued at $306,000 after purchasing an additional 438 shares during the period. California State Teachers Retirement System raised its position in PROCEPT BioRobotics by 1.4% in the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock valued at $2,848,000 after purchasing an additional 693 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: PROCEPT reported quarterly revenue of $94.5 million, ahead of the $92.8 million consensus estimate, with year-over-year growth of 19.3%. The revenue beat helped support the shares despite a modest earnings miss. PROCEPT gains after Q2 beat; Wells Fargo downgrades
• Neutral Sentiment: PROCEPT posted an adjusted loss of $0.47 per share, narrowly worse than the $0.46 consensus estimate. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.53 per share.
• Negative Sentiment: Wells Fargo downgraded PROCEPT to Equal Weight, adding pressure after the earnings report and signaling limited near-term upside in the firm’s view. Wells Fargo downgrades PROCEPT BioRobotics to Equal Weight
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024 through February 25, 2026. The allegations concern weaker-than-expected handpiece sales and excess customer inventory allegedly created by late-quarter bulk discounts. The reports reference an approximately 18% stock decline and larger losses from the class-period high. The allegations have not been proven. PROCEPT securities fraud class action
• Negative Sentiment: Investors have been notified that September 22, 2026 is the lead-plaintiff deadline, increasing visibility around potential litigation costs, disclosure concerns and reputational risk. PROCEPT shareholder alert and lead plaintiff deadline

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.